InMode Ltd. (INMD) Earnings
InMode Ltd. is expected to report next earnings on July 23, 2026 (in NaN days), with a consensus EPS estimate of $0.33. INMD has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -3.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.30 | $0.25 | -16.1% | $82M | +2.7% |
| Nov 5, 2025 | $0.35 | $0.38 | +8.3% | $93M | +2.5% |
| Jul 30, 2025 | $0.43 | $0.47 | +9.3% | $96M | -2.9% |
| Feb 4, 2025 | $0.50 | $0.42 | -16.0% | $98M | -6.8% |
| Oct 30, 2024 | $0.63 | $0.70 | +11.1% | $130M | +13.5% |
| Aug 1, 2024 | $0.38 | $0.34 | -10.5% | $86M | -15.0% |
| May 2, 2024 | $0.41 | $0.32 | -22.0% | $80M | -10.3% |
| Feb 13, 2024 | $0.67 | $0.71 | +6.0% | $127M | +1.4% |
| Nov 2, 2023 | $0.64 | $0.61 | -4.7% | $123M | -6.9% |
| Jul 27, 2023 | $0.64 | $0.72 | +12.5% | $136M | +3.1% |
| May 2, 2023 | $0.47 | $0.52 | +10.6% | $106M | +4.7% |
| Feb 14, 2023 | $0.74 | $0.78 | +5.4% | $134M | +3.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- In North America, new leadership was brought in at the end of Q3 2025, transitioning to a unified model and having the Envision team (ophthalmology and optometry sales force) operate independently. - Internationally, Europe remains a strong region with solid performance, Asia has mixed performance but shows progress in key markets like China. - The PCOR and CO2 lasers are strategically important for long-term growth as they expand the range of procedures physicians can offer. - There are signs of stabilization in the broader market environment, with demand for static procedures pressured but expected to return.
Guidance
Revenues for 2026 are expected to be between $365 million to $375 million. Non-GAAP gross margin is between 74% and 76%. Non-GAAP income from operations is between $73 million and $78 million. Non-GAAP diluted earnings per share are between $1.33 to $1.38.
Segment performance
Total revenue in Q1 2026 was $82 million, up 5% from $77.9 million in the same quarter last year. Growth in Q1 was led by strong performance in the US market. Moving to international operations, sales outside the US totaled $38.7 million in Q1, representing 48% of total sales. Our minimally invasive technology platform accounted for 77% of total revenues. The PCOR and the CO2 laser performed well recently, making a meaningful contribution to our Q1 revenue performance.
Analyst Q&A
Q: Mike Mattson asked about the timeline of the Erbium laser launch, growth of new direct subsidiaries in Argentina and China, and product targeting in China.
A: The erbium laser is expected to get FDA clearance by the end of 2026; Argentina subsidiary was established late 2025, nearly ready with expected Q2 2026 results; in China, using the existing Guangzhou company for the spa and aesthetic arm with special products in development.
Q: Matt Mixick inquired about U.S. Sales Reorg's impact on ophthalmology growth and capital allocation plans.
A: The ophthalmology sales team of 30 covers the US and Canada, early signs of the concept working; capital allocation options include buyback, M&A, dividend considered.
Q: Sam Iver asked about M&A appetite.
A: M&A opportunities are being explored, but private company prices are high; attempted to acquire injectable and toxin companies but offers were not accepted.
Q: Michael Toomey asked about broader aesthetics market and gross margin phasing.
A: Broader aesthetics market faces competition from GLP-1, injectables, etc.; energy-based devices need strategic cooperation; gross margin expected to stay between 74% - 76% through the year